Linerixibat, sold under the brand name Lynavoy, is a medication used for the treatment of cholestatic pruritus. Linerixibat is an ileal bile acid transporter (IBAT) inhibitor. It is taken by mouth. Linerixibat was approved for medical use in the United States in March 2026.
Medical uses Linerixibat is indicated for the treatment of cholestatic pruritus associated with primary biliary cholangitis in adults.
Society and culture
Legal status Linerixibat was approved for medical use in the United States in March 2026.
Names Linerixibat is the international nonproprietary name. Linerixibat is sold under the brand name Lynavoy.
References


